Herein, we report the findings of a randomized, double-blind, placebo-controlled phase I trial of inhalation treatment with the recombinant TFF2-IFN protein in healthy volunteers: a multifunctional candidate for the treatment of COVID-19, in preparation for therapeutic evaluation of COVID-19, influenza, and other respiratory viral infections. The gene discussed is TFF2; the disease is COVID-19.